MX2014015340A - Composiciones y metodos para tratar o evitar infeccion por pneumovirus y enfermedades asociadas. - Google Patents

Composiciones y metodos para tratar o evitar infeccion por pneumovirus y enfermedades asociadas.

Info

Publication number
MX2014015340A
MX2014015340A MX2014015340A MX2014015340A MX2014015340A MX 2014015340 A MX2014015340 A MX 2014015340A MX 2014015340 A MX2014015340 A MX 2014015340A MX 2014015340 A MX2014015340 A MX 2014015340A MX 2014015340 A MX2014015340 A MX 2014015340A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating
associated diseases
pneumovirus infection
Prior art date
Application number
MX2014015340A
Other languages
English (en)
Inventor
Robert O Cook
Eugene R Reynolds
Boris Shekunov
Siead I Zegar
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of MX2014015340A publication Critical patent/MX2014015340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee formas polimórficas cristalinas novedosas de MDT-637, en particular, formas polimórficas cristalinas con propiedades fisicoquímicas específicamente adecuadas para la producción de fármacos, formación amorfa, forma mixta, y métodos para preparar los mismos. Los polimorfos novedosos descritos en la presente descripción son útiles para el tratamiento de enfermedad respiratoria, tal como enfermedad causada por virus sincicial respiratorio.
MX2014015340A 2012-06-29 2013-06-28 Composiciones y metodos para tratar o evitar infeccion por pneumovirus y enfermedades asociadas. MX2014015340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666258P 2012-06-29 2012-06-29
PCT/US2013/048723 WO2014005098A2 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Publications (1)

Publication Number Publication Date
MX2014015340A true MX2014015340A (es) 2015-03-05

Family

ID=49778754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015340A MX2014015340A (es) 2012-06-29 2013-06-28 Composiciones y metodos para tratar o evitar infeccion por pneumovirus y enfermedades asociadas.

Country Status (17)

Country Link
US (2) US9040569B2 (es)
EP (1) EP2867216A4 (es)
JP (1) JP2015524391A (es)
KR (1) KR20150037946A (es)
CN (1) CN104507918A (es)
AU (1) AU2013282286A1 (es)
BR (1) BR112014032290A2 (es)
CA (1) CA2877941A1 (es)
EA (1) EA201590124A1 (es)
HK (2) HK1203956A1 (es)
IL (1) IL236476A0 (es)
IN (1) IN2014DN10680A (es)
MX (1) MX2014015340A (es)
NZ (1) NZ628880A (es)
TW (1) TWI516283B (es)
WO (1) WO2014005098A2 (es)
ZA (1) ZA201409073B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005098A2 (en) 2012-06-29 2014-01-03 Microdose Therapeutx, Inc. Compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2016096143A1 (de) * 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
WO2018071434A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2020056104A1 (en) * 2018-09-14 2020-03-19 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00007394A (es) * 1998-01-29 2003-08-01 Viropharma Inc Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
US6495580B1 (en) * 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2002059132A1 (en) 2001-01-26 2002-08-01 Viropharma Incorporated Intermediate compounds useful for making antiviral compounds
US8202896B2 (en) 2002-08-09 2012-06-19 Microdose Therapeutx, Inc. Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
US8119672B2 (en) * 2002-08-09 2012-02-21 Microdose Therapeutx, Inc. Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2014005098A2 (en) 2012-06-29 2014-01-03 Microdose Therapeutx, Inc. Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Also Published As

Publication number Publication date
WO2014005098A3 (en) 2014-02-27
IL236476A0 (en) 2015-02-26
KR20150037946A (ko) 2015-04-08
WO2014005098A2 (en) 2014-01-03
US20140005239A1 (en) 2014-01-02
BR112014032290A2 (pt) 2017-06-27
EA201590124A1 (ru) 2015-06-30
EP2867216A4 (en) 2015-12-09
US9504672B2 (en) 2016-11-29
NZ628880A (en) 2016-08-26
TWI516283B (zh) 2016-01-11
TW201416093A (zh) 2014-05-01
CN104507918A (zh) 2015-04-08
JP2015524391A (ja) 2015-08-24
HK1203956A1 (en) 2015-11-06
IN2014DN10680A (es) 2015-08-28
HK1210163A1 (en) 2016-04-15
CA2877941A1 (en) 2014-01-03
US9040569B2 (en) 2015-05-26
EP2867216A2 (en) 2015-05-06
AU2013282286A1 (en) 2015-01-22
ZA201409073B (en) 2016-08-31
US20150209328A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2014DN09173A (es)
IN2014DN09805A (es)
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
NZ708928A (en) Mannose derivatives for treating bacterial infections
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX340190B (es) Compuestos para tratar infecciones por virus sincitial respiratorio.
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
MX2014015340A (es) Composiciones y metodos para tratar o evitar infeccion por pneumovirus y enfermedades asociadas.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
WO2013014665A8 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
TW201129572A (en) Compounds for treating respiratory syncytial virus infections
WO2010079045A3 (en) Crystalline salt forms of flibanserine
IN2013DN02555A (es)
IN2014DN03010A (es)
UA104102C2 (en) α-CRYSTALLINE FORM OF CARBABENZPYRIDE
WO2014102820A3 (en) Rivaroxaban intermediate and preparation thereof
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
MX2014006597A (es) Polimeros de condensacion de acido mandelico.